Compare BTDR & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTDR | COGT |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.5B |
| IPO Year | N/A | 2018 |
| Metric | BTDR | COGT |
|---|---|---|
| Price | $10.97 | $39.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 13 |
| Target Price | $28.30 | ★ $30.00 |
| AVG Volume (30 Days) | ★ 6.7M | 2.9M |
| Earning Date | 11-10-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $464,436,000.00 | N/A |
| Revenue This Year | $73.71 | N/A |
| Revenue Next Year | $92.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.40 | N/A |
| 52 Week Low | $6.84 | $3.72 |
| 52 Week High | $27.80 | $43.73 |
| Indicator | BTDR | COGT |
|---|---|---|
| Relative Strength Index (RSI) | 40.56 | 61.77 |
| Support Level | $9.66 | $37.23 |
| Resistance Level | $10.49 | $42.25 |
| Average True Range (ATR) | 0.80 | 2.23 |
| MACD | 0.13 | -0.87 |
| Stochastic Oscillator | 34.70 | 35.13 |
Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.